HemostOD is assembling a novel, cell-based production platform based on natural human biology that makes blood platelets for transfusion in hours, not the days taken by its competitors. In pre-clinical development, the technology manufactures blood platelets outside the body from genetically modified CD34+ adult stem cells, rapidly and scalably, as a substitute to platelets from blood donors, which are in perennial short supply.
More than 20 Swiss biotech companies to exhibit at Bio Europe (startupticker.ch)
HemostOD raises CHF 4.3 million to advance platelet manufacturing platform (venturelab.swiss)
CHF 4.3M to take HemostOD closer to industrial readiness (startupticker.ch)
Venture Leaders Biotech 2025 connects Swiss science with the US biotech market (venturelab.swiss)
HemostOD: The Venture Leader Biotech advancing ex vivo platelet manufacturing (venturelab.swiss)
Venture Leaders Biotech 2025 kick off at Swiss Biotech Day ahead of Boston roadshow (venturelab.swiss)
Venture Leaders Biotech 2025 cohort revealed (startupticker.ch)
Venture Leaders Biotech 2025: 10 innovative startups selected for Boston roadshow (venturelab.swiss)
HemostOD and Emissium get FIT boost (startupticker.ch)
HemostOD et le plus grand centre de transfusion sanguine suisse s'associent (startupticker.ch)
Enerdrape ravit le Trophée PERL 2022 (startupticker.ch)
HemostOD blood platelets Manufacturing gets FIT support (startupticker.ch)
HemostOD raises CHF 1.7 million in Seed round financing (venturekick.ch)
Oversubscribed seed round for Ecublens biotech startup (startupticker.ch)